Expression and Prognostic Value of WDR62 in Hepatocellular Carcinoma

Fuwei ZHANG; Tao WANG; Tao WU

doi:10.12259/j.issn.2095-610X.S20260302

Volume 47 Issue 3

Mar. 2026

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2026 > 47(3): 12-22

Fuwei ZHANG, Tao WANG, Tao WU. Expression and Prognostic Value of WDR62 in Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2026, 47(3): 12-22. doi: 10.12259/j.issn.2095-610X.S20260302

Citation:

Fuwei ZHANG, Tao WANG, Tao WU. Expression and Prognostic Value of WDR62 in Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2026, 47(3): 12-22. doi: 10.12259/j.issn.2095-610X.S20260302

Citation:

PDF( 5646 KB)

Expression and Prognostic Value of WDR62 in Hepatocellular Carcinoma

doi: 10.12259/j.issn.2095-610X.S20260302

Department of Hepatobiliary Surgery，The Second Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101，China

Received Date: 2025-08-20
Available Online: 2026-03-08
Publish Date: 2026-03-31

Abstract

Abstract

Objective To investigate the expression pattern of WD repeat-containing protein 62 （WDR62） in hepatocellular carcinoma （HCC）, its association with clinicopathological features and prognosis, and to construct a prognostic nomogram model for overall survival （OS） based on WDR62. Methods RNA sequencing data and clinical information for HCC were obtained from The Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort （TCGA-LIHC）. WDR62 messenger RNA （mRNA） expression was compared between tumor and adjacent non-tumor liver tissues. Its diagnostic value was assessed using receiver operating characteristic （ROC） curves. Patients were divided into high- and low-expression groups according to the median WDR62 expression level. Associations between WDR62 expression and clinicopathological variables, as well as survival outcomes including OS, disease-specific survival （DSS） and progression-free survival （PFS） were analyzed. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent prognostic factors for OS. Subsequently, a prognostic nomogram was constructed. Harrell’ s concordance index （C-index）, calibration curves and decision curve analysis （DCA） were used to assess model performance. In addition, paired HCC and adjacent liver tissues from surgical specimens in our hospital were collected from the Second Affiliated Hospital of Kunming Medical University, and WDR62 protein expression was examined by immunohistochemistry （IHC）. Results A total of 424 HCC cases and 50 adjacent/normal liver tissues samples from TCGA-LIHC were included. WDR62 mRNA expression was significantly higher in HCC tissues than in adjacent tissues （P < 0.001）, with an area under the ROC curve （AUC） of 0.964 for distinguishing HCC from adjacent/normal tissues. The high WDR62 expression group exhibited higher proportions of patients with pathological stage III-IV, histologic grade G3-G4, alpha-fetoprotein （AFP） >400 ng/mL and the presence of tumor status, and a higher incidence of OS events （P < 0.05）. Kaplan-Meier curves showed significantly poorer OS, DSS and PFS in the high-expression group （OS: P = 0.004）. Multivariate Cox analysis identified pathological T3～T4 stage, presence of tumor status and high WDR62 expression as independent risk factors for OS; high WDR62 expression had a hazard ratio （HR） of 1.656 （95% confidence interval [CI]: 1.028～2.667, P = 0.038）. The nomogram model achieved a Harrell’ s C-index of 0.629 （95%CI: 0.576～0.680）. Calibration curves for 1-, 3- and 5-year OS showed good agreement, and DCA indicated that the model provided higher net benefit within a threshold probability range of approximately 0.05～0.20. In the hospital IHC cohort, WDR62 protein expression was also significantly higher in HCC tissues than in paired adjacent tissues （P < 0.05）. Conclusion WDR62 is up-regulated in HCC and is closely associated with tumor progression and poor prognosis. The OS prognostic nomogram constructed based on WDR62 and clinicopathological variables shows acceptable predictive capability within the TCGA-LIHC cohort.
- Hepatocellular carcinoma,
- WDR62,
- Immunohistochemistry,
- Survival analysis

FullText(HTML)

References(30)

References

[1]	Singh S P, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2025, 15(2): 102446. doi: 10.1016/j.jceh.2024.102446
[2]	Danpanichkul P, Suparan K, Kaeosri C, et al. Global trend of MASH-associated liver cancer: A systematic analysis from the global burden of disease 2021[J]. Clin Gastroenterol Hepatol, 2025, 23(8): 1346-1355. doi: 10.1016/j.cgh.2024.10.026
[3]	Guerrero Negrón L, Buckstein M, Grace M. Gender and ethnic disparities in hepatocellular carcinoma: Trends in incidence rates across U. S. populations from 2000 to 2021[J]. J Clin Oncol, 2025, 43(4_suppl): 524.
[4]	Kim S, Park J, Choi W M, et al. 15-year trends in hepatocellular carcinoma: Epidemiology, treatment, and outcomes from a hospital-based registry[J]. Gut Liver, 2025, 19(5): 746-757.
[5]	Lu X, Qiang M, Li R, et al. Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma[J]. J Transl Med, 2025, 23(1): 1117. doi: 10.1186/s12967-025-07056-3
[6]	Li M, Wang L, Cong L, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma[J]. Hepatology, 2024, 79(3): 560-574. doi: 10.1097/HEP.0000000000000591
[7]	Yin Z, Song Y, Wang L. Single-cell RNA sequencing reveals the landscape of the cellular ecosystem of primary hepatocellular carcinoma[J]. Cancer Cell Int, 2024, 24(1): 379. doi: 10.1186/s12935-024-03574-0
[8]	Yu Y, Li Y, Zhou L, et al. Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses[J]. Cancer Lett, 2024, 604: 217243. doi: 10.1016/j.canlet.2024.217243
[9]	王冬冬, 刘红涛, 陈英. 血清TK-1、Hsp90α联合检测对肝癌高强度聚焦超声消融术疗效的预测效能分析[J]. 河北医科大学学报, 2025, 46(8): 875-880. doi: 10.3969/j.issn.1007-3205.2025.08.002
[10]	焦放, 杨大为, 岳欣, 等. 替诺福韦对乙型肝炎母婴阻断的成本-效果分析[J]. 河北医科大学学报, 2024, 45(11): 1336-1341.
[11]	牟唐维, 梁丹, 赵昱, 等. 免疫细胞功能紊乱在肝衰竭发生和发展中的研究进展[J]. 昆明医科大学学报, 2025, 46(9): 1-14.
[12]	殷瑞, 马国伟, 岳雯溪, 等. 核苷酸类似物单药与联合干扰素治疗慢性乙肝的疗效[J]. 昆明医科大学学报, 2025, 46(6): 79-88. doi: 10.12259/j.issn.2095-610X.S20250610
[13]	杨杰杰, 肖晶晶, 吕超, 等. 原位肝移植患者术后发生早期移植物功能不全的危险因素及其列线图模型构建[J]. 贵州医科大学学报, 2024, 49(10): 1506-1513.
[14]	许键炜, 伍徐娴, 罗晨曦, 等. 苗药腹水草对大鼠肝纤维化的治疗作用及其分子机制[J]. 贵州医科大学学报, 2024, 49(10): 1440-1446. doi: 10.19367/j.cnki.2096-8388.2024.10.005
[15]	Ruaud L, Drunat S, Drunat S, et al. Neurological outcome in WDR62 primary microcephaly[J]. Dev Med Child Neurol, 2022, 64(4): 509-517. doi: 10.1111/dmcn.15060
[16]	Singh S M, Maurya R K, Moirangthem A. Homozygous intragenic deletion in WDR62 in siblings with primary microcephaly[J]. Mol Syndromol, 2025, 16(1): 33-37.
[17]	Bu Y, Zhang L, Ma X, et al. Systematic analysis of the oncogenic role of WDR62 in human tumors[J]. Dis Markers, 2021, 2021: 9940274. doi: 10.1155/2021/9940274
[18]	Baird T, Roychoudhuri R. GS-TCGA Gene set-based analysis of the cancer genome atlas[J]. J Comput Biol, 2024, 31(3): 229-240. doi: 10.1089/cmb.2023.0278
[19]	范松松, 杨立鹏, 赵荣楠, 等. 中国原发性肝癌2022年版诊疗指南与2019年版诊疗规范的比较分析[J]. 中华肿瘤防治杂志, 2022, 29(22): 1575-1578. doi: 10.16073/j.cnki.cjcpt.2022.22.01
[20]	李少玲, 武春燕, 张莉萍, 等. 免疫组化及分子标志物在弥漫性胸膜间皮瘤中的诊断价值[J]. 临床与实验病理学杂志, 2025, 41(6): 706-712. doi: 10.13315/j.cnki.cjcep.2025.06.002
[21]	马长庚, 刘金兰, 刘锦, 等. 大数据分析WDR62在结直肠癌中的表达及临床意义[J]. 潍坊医学院学报, 2022, 44(2): 81-84. doi: 10.16846/j.issn.1004-3101.2022.02.001
[22]	Cai J, Su L, Luo W. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling[J]. Bioengineered, 2022, 13(6): 14450-14459. doi: 10.1080/21655979.2022.2086381
[23]	Chen X, Wei H, Yue A, et al. KPNA2 promotes the progression of gastric cancer by regulating the alternative splicing of related genes[J]. Sci Rep, 2024, 14(1): 17140.
[24]	陈霞. KPNA2调控WDR62可变剪接激活PLK1促进胃癌进展的机制研究[D]. 兰州: 兰州大学, 2023.
[25]	Zhang Y, Tian Y, Yu J J, et al. Overexpression of WDR62 is associated with centrosome amplification in human ovarian cancer[J]. J Ovarian Res, 2013, 6(1): 55. doi: 10.1186/1757-2215-6-55
[26]	Yang Y, Jing W, Zhang L, et al. WDR62 affects the progression of ovarian cancer by regulating the cell cycle[J]. Hereditas, 2025, 162(1): 78. doi: 10.1186/s41065-025-00444-1
[27]	Li X, Guo Y, Qi Z, et al. WDR62 mediates MAPK/ERK pathway to stimulate DNA damage repair and attenuate cisplatin sensitivity in lung adenocarcinoma[J]. Anticancer Drugs, 2025, 36(4): 319-327. doi: 10.1097/CAD.0000000000001682
[28]	陈思文. WDR62受缺氧诱导表达及其在肺癌细胞中的作用研究[D]. 长沙: 湖南师范大学, 2022.
[29]	曾珊. WDR62蛋白在胃癌发生中的作用及其表达与胃癌耐药和预后的相关性研究[D]. 长沙: 中南大学, 2013.
[30]	何进粉. 差异表达的WDR62作为乳腺癌潜在生物标志物的分析[D]. 大理: 大理大学, 2024.

Relative Articles(20)

Relative Articles

[1]	Tong HUANG, Jie HU, Haiting YUAN, Jiahui LI, Wuhua LIN. The Relationship between Peripheral Blood MiR-409-3p，MiR-6861-5p and the Prognosis of TACE in Patients with Hepatocellular Carcinoma. Journal of Kunming Medical University, 2026, 47(3): 1-8.
[2]	Yuhua XIAO, Lingxin YAN, Jidong CAO, Jinhua CHAI. Expression of LMO2 and CAPRIN1 in Pancreatic Cancer Tissues and Their Correlation with Prognosis. Journal of Kunming Medical University, 2025, 46(12): 138-146. doi: 10.12259/j.issn.2095-610X.S20251216
[3]	Zhonghua AI, You HUANG, Xianglong ZHU, Yanchun GAO, Songyuan TANG, Rui PAN. Analysis of Breastfeeding Duration and Influencing Factors of Children Aged 0-5 Years in Yunnan Province. Journal of Kunming Medical University, 2024, 45(2): 112-116. doi: 10.12259/j.issn.2095-610X.S20240215
[4]	Hai ZHOU, Zhongqin YUAN, Yongcun CEN, Yanni LU, Zhihong YAO, Yongchun ZHOU, Yunchao HUANG. Survival Analysis of 1635 Patients with Esophageal Cancer: A Single-Center Retrospective Study. Journal of Kunming Medical University, 2024, 45(8): 67-73. doi: 10.12259/j.issn.2095-610X.S20240810
[5]	Liping ZHUANG, Kaixin WANG, Fang WANG, Hong YE. Expression Characteristics of COX2 and CDX2 in Laryngeal Squamous Cell Carcinoma and Their Prognostic Values in Patients with Laryngeal Squamous Cell Carcinoma. Journal of Kunming Medical University, 2023, 44(5): 47-52. doi: 10.12259/j.issn.2095-610X.S20230529
[6]	Qianting DUAN, Guanshun WANG, Rong DING, Na WANG, Hongli CUN, Ling YANG. Application of CT Radiomics in the Short-Term Prognosis of Combined Therapy for Hepatocellular Carcinoma. Journal of Kunming Medical University, 2023, 44(1): 128-134. doi: 10.12259/j.issn.2095-610X.S20220818
[7]	Da-guang TIAN, Heng-hai YU, Xiao-ping WEI. Effect of Tumor Antigen Loaded DC-CIK on Microenvironment of Hepatocellular Carcinoma. Journal of Kunming Medical University, 2021, 42(1): 46-50. doi: 10.12259/j.issn.2095-610X.S20210127
[8]	Ma Guo Yu , Xiong Qing , Jiang Guo Qing , Yang Jia Tian , Mu Yun Zhen . . Journal of Kunming Medical University, 2020, 41(07): 30-37.
[9]	Zhou Yong Ming , Li Wen Liang . The Progress in the Clinical Research of Lynch Syndrome. Journal of Kunming Medical University, 2018, 39(04): 135-140.
[10]	Liu Bo . Study of the Expression Differences of FHIT Protein in 90 Hepatocellular Tissues with Tissue Chip Method. Journal of Kunming Medical University,
[11]	Zou Hao . . Journal of Kunming Medical University,
[12]	Li Ding Biao . . Journal of Kunming Medical University,
[13]	Ning Jin Mei . . Journal of Kunming Medical University,
[14]	Liu Jian Gang . . Journal of Kunming Medical University,
[15]	Dong Chao . . Journal of Kunming Medical University,
[16]	Hao Ying Hao . . Journal of Kunming Medical University,
[17]	. Expression of Galectin-3 in Cervical Carcinoma and Its Significance. Journal of Kunming Medical University,
[18]	. Clinical Research of the Expression and Correlation of KI-67 and Survivin in Cervical Carcinoma. Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	Yang Xiao Wen . . Journal of Kunming Medical University,